Share on LinkedInShare on LinkedIn

ARTICLE · 23 APRIL 2024

SEC Wins Novel 'Shadow Trading' Trial Against Biopharma Executive

On April 5, 2024, the U.S. Securities and Exchange Commission (SEC) succeeded in its much-watched civil action against Matthew Panuwat, a former business...

CanadaCorporate/Commercial Law

On April 5, 2024, the U.S. Securities and Exchange Commission (SEC) succeeded in its much-watched civil action against Matthew Panuwat, a former business development executive at Medivation Inc., a midcap biopharmaceutical company. The SEC's complaint [PDF] raised a novel theory of insider trading known as "shadow trading". Shadow trading involves the use of material non-public information (MNPI) about a reporting issuer to profit from trading the shares of a different, but "economically linked," company. This case was unique in that the defendant was found liable for using information obtained about Pfizer Inc.'s acquisition of Medivation (the acquired), to profit from trading securities of Medivation's competitor (the competitor) when the Pfizer acquisition (the acquisition) had not yet been publicly announced.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from